Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of setmelanotide in obesity due to MC4R pathway gene variants
2023-507634-24-00Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules, Peptides
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in obesity and hyperphagia comparing Setmelanotide with Placebo (2 arms). Started May 2022; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesityhyperphagia
Beyond the preview
Go deeper on 2023-507634-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507634-24-00.